CDK4/6 inhibition reveals immune-related vulnerabilities in esophageal cancer 🧬🔬

Researchers from the Xavier Bisteau Lab have published a new study in Cell Death & Disease demonstrating that early treatment with the CDK4/6 inhibitor palbociclib can uncover subtype-specific vulnerabilities in esophageal squamous cell carcinoma (eSCC).

Using a combination of multi-omics approaches, high-content imaging, and advanced 3D vascularized microfluidic models, the team identified distinct response patterns to CDK4/6 inhibition across a panel of esophageal cancer cell lines.

While some models were resistant, a specific subgroup displayed delayed proliferation accompanied by DNA damage and micronuclei formation. These events activated the cGAS-STING pathway and interferon-associated transcriptional programs, leading to the production of immune-recruiting chemokines.

To determine whether these molecular changes could translate into functional immune responses, the researchers collaborated with the laboratory of Andrea Pavesi (Nanyang Technological University, Singapore) and employed a vascularized organ-on-chip platform. Remarkably, palbociclib-treated tumor spheroids showed enhanced recruitment of circulating immune cells.

The study provides new evidence that CDK4/6 inhibitors may exert effects beyond cell-cycle arrest and suggests a rationale for exploring immune-oriented therapeutic strategies in selected esophageal cancer subtypes.

Publication: Fabiana Moresi et al., Cell Death & Disease (2026)  https://www.nature.com/articles/s41419-026-08892-x